Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Real-world Effectiveness of the Adjuvanted Recombinant Zoster Vaccine in ≥50-year-old Adults With Autoimmune Diseases

8 Aug 2025

Abstract excerpt

BACKGROUND: Real-world data on the vaccine effectiveness (VE) of the adjuvanted recombinant zoster vaccine (RZV) to prevent herpes zoster (HZ) among individuals with autoimmune diseases (AIDs) are limited. To address this knowledge gap, we aimed to evaluate the VE of 2 RZV doses against HZ in ≥50-year-old adults with selected AIDs (rheumatoid arthritis, inflammatory bowel disease, systemic lupus erythematosus,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytomegalovirus and herpesvirus research
Share to Herpesvirus Infections and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40795879
DOI: 10.1093/infdis/jiaf395

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Real-world Effectiveness of the Adjuvanted Recombinant Zoster Vaccine in ≥50-year-old Adults With Autoimmune DiseasesPMID 40795879Read ↗

Recombinant Zoster Vaccine Uptake and Risk of Flares Among Older Adults With Immune‐Mediated Inflammatory Diseases in the USSemantic proximity Read ↗

Immune response to an adjuvanted recombinant zoster vaccine in Japanese patients with rheumatoid arthritis receiving upadacitinib (End Zoster-J study)Semantic proximity Read ↗

COVID-19 vaccines and autoimmune disorders: A scoping review protocolSemantic proximity Read ↗

Efficacy and side effects of the Herpes Zoster vaccine in immunocompromised individuals – a systematic reviewSemantic proximity Read ↗

Safety of Coronavac and ChAdOx1 Vaccines Against SARS-CoV-2 in Patients with Rheumatoid Arthritis Data from the Brazilian Multicentric Study SaferSemantic proximity Read ↗

Immune response to the recombinant herpes zoster vaccine in people living with HIV over 50 years of age compared to non-HIV age-/gender-matched controls (SHINGR’HIV): a multicenter, international, non-randomized clinical trial study protocolSemantic proximity Read ↗

Increased Risk of Herpes Zoster in Rheumatoid Arthritis Is Not Only Due to Jak Inhibitors: Study of 392 Patients from a Single University CenterSemantic proximity Read ↗

Anti-SARS-CoV-2 immunogenicity decay and incident cases six months after Sinovac-CoronaVac inactivated vaccine in autoimmune rheumatic diseases patients: phase 4 prospective trialSemantic proximity Read ↗

COVID-19 Infection and Efficacy of Vaccination in Patients with Rheumatic Diseases During Omicron Outbreak in South Korea: A Prospective Cohort StudySemantic proximity Read ↗

Examining the Immunological Effects of COVID-19 Vaccination in Patients with Conditions Potentially Leading to Diminished Immune Response Capacity – The OCTAVE TrialSemantic proximity Read ↗

Methotrexate and Tumor Necrosis Factor Inhibitors Independently Decrease Neutralizing Antibodies after SARS-CoV-2 Vaccination: Updated Results from the SUCCEED StudySemantic proximity Read ↗

Effects of the Second Dose of COVID-19 Vaccines in Patients with Autoimmune Rheumatic Diseases with Hybrid ImmunitySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.